We observed a significant increase in the fraction of EGFR-activated fibroblasts post treatment and found that an increased frequency of this cell type was associated with greater post-treatment residual tumor burden (pathologically measured longest tumor length) (Appendix Fig. S3). This evidence concerns the gene EGFR and neoplasm.